Traditionally, IP counselors are buffered from the senior-executive decision-making process. Although patent attorneys represent an elite group that have a scientific background, this technical background many times prevents you from being a part of top-level strategic decisions. With your subject-matter expertise, and our ability to convert the complexities of the patent space into actionable business intelligence, you can earn a seat in the executive board room. Connie from Lee & Hayes says, " As an IP attorney, I specialize in life sciences technologies and need tools that go beyond a good search. I use IP Street's suite of tools because the analysis provides great business insights in a fraction of the time it used to take, allowing me to be more responsive to my clients with better information. As a result, I am able to play a more integral role in my clients' business. " It is about time you can communicate actionable business intelligence from patent documents. Executives are starting to recognize the importance of Intellectual Assets and their management, but they need more. An you can provide it for them. The idea for IP Street originated with Lee, a co-founder of the US's top ranked firm for patent quality, Lee & Hayes (Spokane, Seattle, Austin, Portland, Taipei, and Beijing). Lee became engrossed in the notion of mining IP data to plot business strategy when he was hired by an investment bank to predict the likely outcomes of the landmark NTP v. Research In Motion case. In the time since, he and his firm have come to represent six of the 10 largest patent filers in the United States, and Lee has become a recognized evangelist on the rise of intellectual assets in the U.S., China, and beyond. Lee gathered his colleagues at Lee & Hayes, some IP experts and others business strategists, raised funds, and went to work assembling the technologies and talent behind IP Street today. Proper organization of a patent porfolio is essential to be prepared to properly navigate the IP landscape. One key issue is related to inventorship. Consider the Pfizer patent, patent # 5,760,06^, which is commonly known as the COX-2 inhibitor. Pfizer is currently in a $1B lawsuit because Searle, the original owner of the patent, failed to include a key inventor on the patent. Pfizer inherited this mess when they acquired Pharmacia, who had previously acquired Monsanto, who had previously acquired Searle. Ignorance is not a defensible excuse in patent litigation. |